Pyomyositis Market Outlook:
Pyomyositis Market size was over USD 27.07 billion in 2025 and is anticipated to cross USD 42.85 billion by 2035, witnessing more than 4.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of pyomyositis is assessed at USD 28.22 billion.
The increasing prevalence of chronic diseases such as diabetes has increased the likelihood of developing pyomyositis. Chronic diseases compromise the immune system, making patients more vulnerable to bacterial infections such as pyomyositis. The rising prevalence of chronic diseases has fueled the growth of the pyomyositis market and is expected to do so in the coming years. According to WHO, about 422 million worldwide have diabetes, and 1.5 million deaths are directly attributed to diabetes each year.
Pyomyositis is a rare bacterial infection that affects the muscles, often leading to abscess formation within the muscle tissue. It is more commonly found in tropical and subtropical regions but can occur in other parts of the world as well. The infection typically arises from Staphylococcus aureus bacteria and may develop due to factors like trauma, skin injuries, or underlying conditions that weaken the immune system. The market for pyomyositis treatment is relatively small compared to more common diseases, but it exists and may involve pharmaceutical companies, medical device manufacturers, and healthcare providers. Patient advocacy groups may play a role in supporting those affected by pyomyositis, helping to raise awareness and advocating for research and treatment options.
